Literature DB >> 31552595

Dysregulation of non-histone molecule miR205 and LRG1 post-transcriptional de-regulation by SETD1A in triple negative breast cancer.

Ezanee Azlina Mohamad Hanif1.   

Abstract

FEC chemo-resistance in triple negative breast cancer (TNBC) remains a challenge. Therefore it is crucial to determine the right treatment regime by understanding molecular mechanisms of driver regulators involved in the progression of TNBCs. This study aims to understand SETD1A mechanisms in TNBC development in two TNBC cell lines. SETD1A was transiently transfected in MDA-MB-468 (FEC good prognosis) and Hs578T (FEC poor prognosis). Regulation of potential targets miR205, EMT marker ZEB1 and LRG1 and proliferative marker Ki-67 were tested by RqPCR to elucidate SETD1A interactions. This study displayed significant recovery of miR205 with SETD1A depletion and reduction of ZEB1 in MDA-MB-468. However, ZEB1 remained unchanged in Hs578T indicating ZEB1 regulation may be outcompeted by other mechanisms associated with aggressive cell line characteristics and the expression of endogenous ZEB1 was relatively high in Hs578T. Elevation of LRG1 and declined Ki-67 were observed by SETD1A knocked down. Enhanced expression was observed by LRG1 in Hs578T and not in MDA-MB-468 suggesting LRG1 contributed to distinct poor FEC outcome in TNBCs. The underlying mechanism of SETD1A in miR205/ZEB1/Ki-67/LRG1 axis needs further evaluation. Whether abrogation of the pathway is indeed associated with transcriptional or post-transcriptional activation in TNBC cell lines models, clearly validation in clinical samples is warranted to achieve its prognostic and therapeutic values in TNBCs.

Entities:  

Keywords:  EMT; SETD1A; TNBCs; Triple negative breast cancers; miR205

Mesh:

Substances:

Year:  2019        PMID: 31552595     DOI: 10.1007/s11033-019-05079-w

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  29 in total

1.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.

Authors:  Brian D Lehmann; Joshua A Bauer; Xi Chen; Melinda E Sanders; A Bapsi Chakravarthy; Yu Shyr; Jennifer A Pietenpol
Journal:  J Clin Invest       Date:  2011-07       Impact factor: 14.808

Review 2.  Triple-negative breast cancer.

Authors:  Gert Stockmans; Karen Deraedt; Hans Wildiers; Philippe Moerman; Robert Paridaens
Journal:  Curr Opin Oncol       Date:  2008-11       Impact factor: 3.645

3.  Gene expression profiling identifies molecular subtypes of inflammatory breast cancer.

Authors:  François Bertucci; Pascal Finetti; Jacques Rougemont; Emmanuelle Charafe-Jauffret; Nathalie Cervera; Carole Tarpin; Catherine Nguyen; Luc Xerri; Rémi Houlgatte; Jocelyne Jacquemier; Patrice Viens; Daniel Birnbaum
Journal:  Cancer Res       Date:  2005-03-15       Impact factor: 12.701

4.  A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes.

Authors:  Richard M Neve; Koei Chin; Jane Fridlyand; Jennifer Yeh; Frederick L Baehner; Tea Fevr; Laura Clark; Nora Bayani; Jean-Philippe Coppe; Frances Tong; Terry Speed; Paul T Spellman; Sandy DeVries; Anna Lapuk; Nick J Wang; Wen-Lin Kuo; Jackie L Stilwell; Daniel Pinkel; Donna G Albertson; Frederic M Waldman; Frank McCormick; Robert B Dickson; Michael D Johnson; Marc Lippman; Stephen Ethier; Adi Gazdar; Joe W Gray
Journal:  Cancer Cell       Date:  2006-12       Impact factor: 31.743

Review 5.  Targeting triple negative breast cancer: is p53 the answer?

Authors:  Natalie Turner; Erica Moretti; Olimpia Siclari; Ilenia Migliaccio; Libero Santarpia; Maurizio D'Incalci; Stefano Piccolo; Andrea Veronesi; Alberto Zambelli; Gianni Del Sal; Angelo Di Leo
Journal:  Cancer Treat Rev       Date:  2013-01-12       Impact factor: 12.111

6.  Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes.

Authors:  Amy Willis; Eun Joo Jung; Therese Wakefield; Xinbin Chen
Journal:  Oncogene       Date:  2004-03-25       Impact factor: 9.867

7.  Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.

Authors:  Cornelia Liedtke; Chafika Mazouni; Kenneth R Hess; Fabrice André; Attila Tordai; Jaime A Mejia; W Fraser Symmans; Ana M Gonzalez-Angulo; Bryan Hennessy; Marjorie Green; Massimo Cristofanilli; Gabriel N Hortobagyi; Lajos Pusztai
Journal:  J Clin Oncol       Date:  2008-02-04       Impact factor: 44.544

Review 8.  The p53 pathway in breast cancer.

Authors:  Milena Gasco; Shukri Shami; Tim Crook
Journal:  Breast Cancer Res       Date:  2002-02-12       Impact factor: 6.466

9.  MicroRNA profile in very young women with breast cancer.

Authors:  Maria Peña-Chilet; Maria T Martínez; Jose A Pérez-Fidalgo; Lorena Peiró-Chova; Sara S Oltra; Eduardo Tormo; Elisa Alonso-Yuste; Beatriz Martinez-Delgado; Pilar Eroles; Joan Climent; Octavio Burgués; Jaime Ferrer-Lozano; Ana Bosch; Ana Lluch; Gloria Ribas
Journal:  BMC Cancer       Date:  2014-07-21       Impact factor: 4.430

10.  Mutant p53 regulates Dicer through p63-dependent and -independent mechanisms to promote an invasive phenotype.

Authors:  Patricia A J Muller; Antonio G Trinidad; Patrick T Caswell; Jim C Norman; Karen H Vousden
Journal:  J Biol Chem       Date:  2013-11-12       Impact factor: 5.157

View more
  2 in total

Review 1.  The role of leucine-rich alpha-2-glycoprotein-1 in proliferation, migration, and invasion of tumors.

Authors:  Meng Lin; Jinmeng Liu; Fengping Zhang; Gaoxiu Qi; Shuqi Tao; Wenyuan Fan; Min Chen; Kang Ding; Fenghua Zhou
Journal:  J Cancer Res Clin Oncol       Date:  2022-01-17       Impact factor: 4.553

Review 2.  Research Progress on Leucine-Rich Alpha-2 Glycoprotein 1: A Review.

Authors:  Yonghui Zou; Yi Xu; Xiaofeng Chen; Yaoqi Wu; Longsheng Fu; Yanni Lv
Journal:  Front Pharmacol       Date:  2022-01-05       Impact factor: 5.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.